Management of Non-Alcoholic Fatty Liver Disease in a Patient with Type 2 Diabetes: A Case Study

Janice is a 45yo Caucasian female with symptoms of Non Alcoholic Fatty Liver Disease.Her BMI is 40 and she was diagnosed with DM type 2 3 years ago. Her last HgbA1c was 7.4. She lives a sedentary life style. She state she has significant fatigue and but is otherwise asymptomatic. What diagnostics would you order for Janice? Why? What treatment plan would you recommend for her? What is her prognosis? 2 references APA 7th edition

ANSWER

Diagnostics for Janice:

Liver Function Tests (LFTs): Perform liver function tests to assess liver enzymes such as ALT (alanine aminotransferase), AST (aspartate aminotransferase), and GGT (gamma-glutamyl transferase). Elevated levels of these enzymes may indicate liver inflammation and damage, which are common in Non-Alcoholic Fatty Liver Disease (NAFLD).

Imaging Studies:

– Abdominal Ultrasound: Utilize abdominal ultrasound to evaluate the liver for signs of fatty infiltration, hepatomegaly, and the presence of liver steatosis.

– FibroScan or Transient Elastography: Consider advanced imaging modalities like FibroScan to assess liver stiffness and fibrosis, which are crucial for determining the severity and progression of NAFLD.

Liver Biopsy (Optional): Although not always necessary, a liver biopsy may be considered in cases where the diagnosis is uncertain or when there is a need to assess the degree of liver fibrosis and inflammation accurately.

Treatment Plan for Janice:

Weight Loss and Lifestyle Modification:

– Given Janice’s high BMI and sedentary lifestyle, weight loss through diet and exercise is paramount. Encourage her to adopt a balanced, calorie-restricted diet rich in fruits, vegetables, whole grains, and lean protein, while limiting saturated fats, refined sugars, and processed foods.

– Implement a structured exercise regimen comprising aerobic exercises (e.g., brisk walking, swimming) and resistance training to improve insulin sensitivity, promote weight loss, and reduce liver fat accumulation.

Control of Type 2 Diabetes:

– Optimize glycemic control to reduce the risk of disease progression and complications associated with NAFLD. Aim for a target HgbA1c level below 7% through a combination of oral antidiabetic medications, insulin therapy if necessary, and lifestyle modifications.

– Consider medications with potential benefits for both glycemic control and liver health, such as metformin and sodium-glucose cotransporter-2 (SGLT-2) inhibitors.

Pharmacotherapy for NAFLD:

– While there are currently no FDA-approved pharmacological treatments specifically for NAFLD, consider off-label use of medications such as vitamin E or pioglitazone in selected cases to reduce liver inflammation and fibrosis. However, weigh the potential benefits against the risks and individual patient factors.

Regular Monitoring and Follow-Up:

– Schedule regular follow-up visits to monitor Janice’s liver function, glycemic control, weight loss progress, and overall well-being. Adjust the treatment plan as needed based on her response to therapy and any emerging clinical developments.

Prognosis for Janice:

The prognosis for Janice largely depends on her ability to adhere to lifestyle modifications, achieve sustained weight loss, and effectively manage her type 2 diabetes. With early intervention and comprehensive management, including weight loss, glycemic control, and addressing underlying metabolic abnormalities, the progression of NAFLD can be slowed or even reversed in some cases. However, Janice’s condition may carry an increased risk of developing complications such as advanced liver fibrosis, cirrhosis, and cardiovascular disease if left untreated or inadequately managed.

References:

Chalasani, N., Younossi, Z., Lavine, J. E., Charlton, M., Cusi, K., Rinella, M., … & Sanyal, A. J. (2018). The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology, 67(1), 328-357.

American Diabetes Association. (2020). 6. Glycemic targets: Standards of Medical Care in Diabetes—2020. Diabetes Care, 43(Supplement 1), S66-S76.